2021
P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009
Harrington K, Cohen E, Siu L, Rischin D, Licitra L, Vermorken J, Le Q, Tahara M, Machiels J, Hawk N, Ge J, Bidadi B, Swaby R, Burtness B. P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. Oral Oncology 2021, 118: 10-11. DOI: 10.1016/s1368-8375(21)00381-x.Peer-Reviewed Original Research
2020
Chapter 11 Trials and tribulations: Clinical trials and the future
Khanna S, Burtness B. Chapter 11 Trials and tribulations: Clinical trials and the future. 2020, 197-215. DOI: 10.1016/b978-0-12-820679-9.00011-6.Peer-Reviewed Original ResearchClinical trialsNeck cancerRecent landmark trialsRole of immunotherapyRisk stratification toolPromising clinical trialsMetastatic headPoor accrualSystemic treatmentLandmark trialsNeck specialistsStratification toolDedicated headTrialsCurrent standardCancerExciting advancesLack of fundingHeadImmunotherapyHPVHNSCCTherapyDiseasePathobiology
2016
Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma
Baxi SS, Dunn LA, Burtness BA. Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma. Oral Oncology 2016, 62: 147-148. PMID: 27776933, DOI: 10.1016/j.oraloncology.2016.10.007.Peer-Reviewed Original Research
2015
Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer
Cohen E, Moore K, Slomovitz B, Chung C, Anderson M, Morris S, Mauro D, Burtness B. Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer. Journal For ImmunoTherapy Of Cancer 2015, 3: p147. PMCID: PMC4645484, DOI: 10.1186/2051-1426-3-s2-p147.Peer-Reviewed Original Research